Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

By C. Kearon, Elie A. Akl, J. Ornelas, Allen J. Blaivas, D. Jiménez, H. Bounameaux, M. Huisman, C. King, T. Morris, N. Sood and 5 more. Chest, 2012

4,568 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0e6eac07698810303b1925e15c922aa9efca30ad

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Rosenkranz
2. S. Schulman
3. Joshua A. Beckman

In Internal Medicine

1. M. Cushman
2. Samuel Z. Goldhaber
3. S. Konstantinides

In Pulmonary and Respiratory Medicine

1. Joshua A. Beckman

Citations in the corpus

• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin dosing: 2017 Update (2017, neutral): “(4) Kearon, C. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 149, 315-52 (2016). (5) Shehab, N., Sperling, L.S., Kegler, S.R. & Budnitz, D.S. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus ”
• EULAR recommendations for the management of antiphospholipid syndrome in adults (2019, neutral): “The panel recommended a duration of anticoagulation according to international guidelines for patients without APS 30 because the benefit of long-term anticoagulation in this population is unclear.”
• COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, background): “Recurrent PE despite optimal anticoagulation, or clinically-significant VTE in the setting of abs olute contraindications to anticoagulation would be among the few scenarios in which placement of an inferior vena cava filter may be considered (11).”